NCT04956276View on ClinicalTrials.gov

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2022

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2024

Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
DRUG

ALXN1830

Administered as an SC infusion.

DRUG

Placebo

Administered as an SC infusion.

Trial Locations (1)

90602-3171

Clinical Study Site, Riverside

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY